Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUDITH L WHITE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1316940018
CMS profile
14471
Location
KINGSPORT, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,672.68

17 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,131.05 8
Food and Beverage $541.63 9

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $1,672.68 17

Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUDITH L WHITE

NPI 1316940018 · CMS profile ID 14471

Allopathic & Osteopathic Physicians / Internal Medicine

KINGSPORT, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316940018?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUDITH L WHITE, NPI 1316940018, CMS profile ID 14471. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316940018?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JUDITH L WHITE, NPI 1316940018, CMS profile ID 14471. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316940018?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JUDITH L WHITE, NPI 1316940018, CMS profile ID 14471, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–17 of 17 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1316940018?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

17 matching records · $1,672.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 17 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–17 of 17.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $75.0010/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101231751 CMS
E.R. Squibb & Sons, L.L.C. $27.7310/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101231753 CMS
E.R. Squibb & Sons, L.L.C. $70.0010/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101231755 CMS
E.R. Squibb & Sons, L.L.C. $155.8610/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101231757 CMS
E.R. Squibb & Sons, L.L.C. $385.8110/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101231759 CMS
E.R. Squibb & Sons, L.L.C. $16.4210/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101231761 CMS
E.R. Squibb & Sons, L.L.C. $16.4210/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101231763 CMS
E.R. Squibb & Sons, L.L.C. $64.0010/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101231765 CMS
E.R. Squibb & Sons, L.L.C. $27.7310/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101231767 CMS
E.R. Squibb & Sons, L.L.C. $75.0010/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101231769 CMS
E.R. Squibb & Sons, L.L.C. $27.7310/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101231771 CMS
E.R. Squibb & Sons, L.L.C. $70.0010/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101231773 CMS
E.R. Squibb & Sons, L.L.C. $140.7110/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101231775 CMS
E.R. Squibb & Sons, L.L.C. $27.7310/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101231777 CMS
E.R. Squibb & Sons, L.L.C. $225.9410/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101231779 CMS
E.R. Squibb & Sons, L.L.C. $40.6610/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101231781 CMS
E.R. Squibb & Sons, L.L.C. $225.9410/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101231783 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $485.12 28
PY2021 $2,163.83 6
PY2022 $51.76 3
PY2024 $1,672.68 17

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $640,741.74 27
PY2024 Principal investigator $267,189.88 19
PY2023 Recipient $98.80 1
PY2023 Principal investigator $96,720.88 105
PY2022 Recipient $85.00 1
PY2022 Principal investigator $1,700,193.53 16,257
PY2021 Recipient $242.50 1
PY2021 Principal investigator $910,699.42 50
PY2020 Recipient $1,336.87 14
PY2020 Principal investigator $850,450.68 67
PY2019 Principal investigator $1,175,554.95 90

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $23,215.06 12/31/2021 Non-covered Recipient Entity
SYNEXUS RESEARCH
A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals with Pre-cirrhotic Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 848751527
Principal investigator 1 Merck Sharp & Dohme Corporation $424.81 12/31/2021 Non-covered Recipient Entity
SYNEXUS RESEARCH
A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals with Pre-cirrhotic Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 848751529
Principal investigator 1 Merck Sharp & Dohme Corporation $16,043.80 12/17/2021 Non-covered Recipient Entity
SYNEXUS RESEARCH
A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals with Pre-cirrhotic Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 848751497
Principal investigator 1 Eli Lilly and Company $284.81 12/09/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A MASTER PROTOCOL FOR RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF CHRONIC PAIN No dispute reported 06/30/2026 819454863
Principal investigator 1 Eli Lilly and Company $20,946.00 11/29/2021 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
A MASTER PROTOCOL FOR RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF CHRONIC PAIN No dispute reported 06/30/2026 819454249
Principal investigator 1 Nevro Corp. $2,338.56 11/23/2021 Non-covered Recipient Entity
Compass Research
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 832288485
Principal investigator 1 Eli Lilly and Company $884.05 11/18/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3526318 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 819455421
Principal investigator 1 Eli Lilly and Company $18.14 11/15/2021 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 819454251
Principal investigator 1 Janssen Research & Development, LLC $255.00 11/01/2021 Non-covered Recipient Entity
Optimal Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787729273
Principal investigator 1 Janssen Research & Development, LLC $3,213.00 10/18/2021 Non-covered Recipient Entity
Optimal Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787730089
Principal investigator 1 Janssen Research & Development, LLC $445.00 10/08/2021 Non-covered Recipient Entity
Optimal Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787730039
Principal investigator 1 Janssen Research & Development, LLC $3,735.00 09/30/2021 Non-covered Recipient Entity
Optimal Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787729991
Principal investigator 1 Eli Lilly and Company $884.05 09/27/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A MASTER PROTOCOL FOR RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF CHRONIC PAIN No dispute reported 06/30/2026 819454391
Principal investigator 1 Nevro Corp. $1,050.00 09/16/2021 Non-covered Recipient Entity
Compass Research
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 832288483
Principal investigator 1 Janssen Research & Development, LLC $7,821.00 08/26/2021 Non-covered Recipient Entity
Optimal Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787729945
Principal investigator 1 Nevro Corp. $5,859.84 08/18/2021 Non-covered Recipient Entity
Compass Research
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 832288487
Principal investigator 1 Janssen Research & Development, LLC $13,491.00 08/09/2021 Non-covered Recipient Entity
Optimal Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787729257
Principal investigator 1 Eli Lilly and Company $461.41 07/15/2021 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 819454011
Principal investigator 1 Allergan, Inc. $16,549.25 06/23/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789013473
Principal investigator 1 Eli Lilly and Company $29.00 05/31/2021 Non-covered Recipient Entity
ANDROSCOGGIN CARDIO ASSOC DBA MAINE RSRH ASSOC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 819451087
Principal investigator 1 Eli Lilly and Company $3,331.80 05/26/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A MASTER PROTOCOL FOR RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF CHRONIC PAIN No dispute reported 06/30/2026 819454859
Principal investigator 1 Janssen Research & Development, LLC $7,440.00 05/19/2021 Non-covered Recipient Entity
Optimal Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787729910
Principal investigator 1 Nevro Corp. $5,102.40 05/06/2021 Non-covered Recipient Entity
Compass Research
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 832288477
Principal investigator 1 Allergan, Inc. $4,538.36 05/01/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789013471
Principal investigator 1 Eli Lilly and Company $339.50 04/30/2021 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 819452437
Principal investigator 1 Eli Lilly and Company $29.00 04/30/2021 Non-covered Recipient Entity
NEW HORIZON RESEARCH CENTER
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 819460475
Principal investigator 1 Eli Lilly and Company $3,560.99 04/27/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
MASTER PROTOCOL FOR RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF CHRONIC PAIN No dispute reported 06/30/2026 819454861
Principal investigator 1 Eli Lilly and Company $682.62 04/27/2021 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 819466165
Principal investigator 1 Eli Lilly and Company $2,067.63 04/27/2021 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 819468509
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $74.00 04/22/2021 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 789132733
Principal investigator 1 Janssen Research & Development, LLC $2,305.00 04/21/2021 Non-covered Recipient Entity
Optimal Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787729897
Principal investigator 1 Eli Lilly and Company $142,753.00 04/20/2021 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF OSTEOARTHRITIS No dispute reported 06/30/2026 819453895
Principal investigator 1 Eli Lilly and Company $106,684.00 04/20/2021 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 819453993
Principal investigator 1 Eli Lilly and Company $79,276.00 04/20/2021 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 819454061
Principal investigator 1 Eli Lilly and Company $28,049.00 04/20/2021 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 819455337
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $10,359.00 04/09/2021 Non-covered Recipient Entity
Compass Research LLC
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 789134031
Principal investigator 1 Janssen Research & Development, LLC $7,780.00 04/08/2021 Non-covered Recipient Entity
Optimal Research, Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants No dispute reported 06/30/2026 787729881
Principal investigator 1 Allergan, Inc. $7,548.70 03/17/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789013469
Principal investigator 1 Nevro Corp. $6,398.40 02/26/2021 Non-covered Recipient Entity
Compass Research
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 832288489
Principal investigator 1 Nevro Corp. $6,398.40 02/26/2021 Non-covered Recipient Entity
Compass Research
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 832288493
Principal investigator 1 Nevro Corp. $75.00 02/18/2021 Non-covered Recipient Entity
Compass Research
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 832288479
Recipient Eli Lilly and Company $242.50 01/29/2021 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 819445205
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $1,325.11 01/26/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 819455031
Principal investigator 1 Eli Lilly and Company $1,189.59 01/26/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF OSTEOARTHRITIS No dispute reported 06/30/2026 819454385
Principal investigator 1 Eli Lilly and Company $5,907.04 01/26/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 819455025
Principal investigator 1 Eli Lilly and Company $4,779.30 01/26/2021 Non-covered Recipient Entity
RADIANT RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 819467491
Principal investigator 1 Allergan, Inc. $3,499.80 01/25/2021 Non-covered Recipient Entity
COMPASS RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789013467
Principal investigator 1 Nevro Corp. $75.00 01/21/2021 Non-covered Recipient Entity
Compass Research
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 832288481
Principal investigator 1 Nevro Corp. $75.00 01/21/2021 Non-covered Recipient Entity
Compass Research
Chronic Peripheral Polyneuropathy Randomized Trial No dispute reported 06/30/2026 832288491
Principal investigator 1 Eli Lilly and Company $289,659.00 01/05/2021 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 819453789
Principal investigator 1 Eli Lilly and Company $61,448.00 01/05/2021 Non-covered Recipient Entity
CLINICAL RESEARCH ADVANTAGE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 819453881